<DOC>
	<DOCNO>NCT02112838</DOCNO>
	<brief_summary>The purpose study determine whether fostamatinib safe effective treatment IgA Nephropathy</brief_summary>
	<brief_title>Safety Efficacy Study Fostamatinib Treat Immunoglobin A ( IgA ) Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Renal biopsy finding consistent IgA nephropathy Treatment Angiotensin Converting Enzyme inhibitor ( ACEi ) and/or Angiotensin II Receptor Blocker ( ARB ) least 90 day maximum approved ( tolerate ) dose Proteinuria &gt; 1 gm/day diagnosis IgA nephropathy Proteinuria &gt; 0.50 gm/day second Screening Visit Blood pressure control â‰¤ 130/80 angiotensin blockade without antihypertensive agent Recent use cyclophosphamide , mycophenolate mofetil , azathioprine , Rituximab . Use &gt; 15 mg/day prednisone ( corticosteroid equivalent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IGA Glomerulonephritis</keyword>
	<keyword>Nephritis , IGA Type</keyword>
</DOC>